Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.9701 +0.0078 (+0.81%)
Streaming Delayed Price Updated: 9:50 AM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 Next >
News headline image
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Via ACCESS Newswire
News headline image
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
Via ACCESS Newswire
News headline image
Sunshine Biopharma Stock is 34% Higher Since September as Investors Reward Performance Combined with Innovation (NASDAQ: SBFM)
Via AB Newswire
News headline image
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
Via ACCESS Newswire
News headline image
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Via ACCESS Newswire
News headline image
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct
Via Investor Brand Network
News headline image
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Via ACCESS Newswire
News headline image
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Via ACCESS Newswire
News headline image
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Via ACCESS Newswire
News headline image
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Via ACCESSWIRE
News headline image
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
Via ACCESSWIRE
News headline image
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
News headline image
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
Via ACCESSWIRE
News headline image
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
News headline image
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
Via ACCESSWIRE
News headline image
Sunshine Biopharma Launches Two New Generic Prescription Drugs
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.